Science Speaks continues its interview series exploring the global HIV and tuberculosis research and development efforts at the U.S. Centers for Disease Control and Prevention (CDC) with a conversation with Bess Miller, MD, MSc, who works in the Division of Global HIV/AIDS. Dr. Miller has served as associate director and team lead for HIV/TB, providing leadership in policy and implementation of TB/HIV activities in 43 resource-limited countries supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). She has worked to align PEPFAR TB/HIV priorities with the World Health Organization (WHO) policies on TB/HIV, and on the use of antiretroviral therapy (ART) in people living with HIV (PLHIV). In this interview Dr. Miller discusses the successes and challenges in implementing TB infection control in Africa, progress in deploying the GeneXpert MTB/RIF rapid TB diagnostic on the ground there, and how efforts to scale up access to ART are helping achieve goals in TB control and elimination.
U = U: The evidence is in. Spreading the word that undetectable = untransmissable is the next crucial step
By Murray Penner of Prevention Access Campaign Undetectable = Untransmittable, or U=U, is a clear, effective, simple way to convey the fact that a person living […]
CDC announces publication of TB treatment trial results showing four month regimen as effective as six month
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]